Conference Description:

Join Oxford Global for the inaugural Advances in Immuno-Oncology USA Congress on the 11th – 12th October 2018 in San Diego, USA. There will be over 350 delegates representing global pharmaceutical organisations, leading biotech companies, and internationally renowned academic institutions.

View Agenda: https://bit.ly/2vrwiwW

Hear from leading experts within the immuno-oncology field through over 20 presentations, case studies and panel discussions focuser on the latest innovations in Car-T cell development, patient stratification, and assay developments in the immuno-oncology world.

2 Interactive Streams:
• Development of Immuno-Oncology Therapies – Stream 1 features presentations on the latest developments in T Cell Engagers, cell based functional assays for IDO inhibitors, harnessing novel immune escape mechanisms for cancer therapeutics and toxicities with immuno-oncology therapy
• Translational Immuno-Oncology and Clinical Based Development – Stream 2 addresses talks on the latest patient stratification innovations in immuno-oncology, identifying immunological biomarkers for precision cancer immunotherapy and biomarker based selections in clinical trials.

Register for our live, pre-congress webinar for free today: https://bit.ly/2IrjJXR
The Role for TNFR2 in the Tumor Microenvironment
Thursday 14th June 2018, 4pm BST
Presented by Russell LaMontagne, Chief Executive Officer: Boston Immune Technologies and Therapeutics Inc
For further information regarding prices and possible discounts, please contact Danielle Dalby on [email protected] or call +44 (0)1865 248 455.